This review analyzes therapies for improving kidney health in individuals with diabetic kidney disease, highlighting key interventions.
The global prevalence of chronic kidney disease (CKD) from all causes is increasing with parallel increases in the number of people undergoing renal replacement therapy and increases in costs of care. The pathophysiology of diabetic kidney disease (DKD) is complex and heterogeneous. Clinical trials have shown benefits in renal outcomes with drugs acting on the renin-angiotensin-aldosterone system (RAAS) axis, as well as sodium-glucose cotransporter 2 (SGLT2) inhibitors, and GLP1RA. In this manuscript we review the management of diabetic kidney disease.
No takes yet. Share an insight, caveat, or question.
U. Ayyagari (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: